There is still a lack of knowledge on the characteristics of super responders (SRs) during treatment with bimeki- zumab, since genetic, clinical, and biomarkers investiga- tions are required. During bimekizumab treatment, a high rate of SRs was demonstrated at early clinical timepoints, with some interesting diferences between SRs and non-super- respnders.
Super Responder Profle Under Bimekizumab Treatment in Moderate‐to‐Severe Psoriasis: A Short Term Real‐Life Observation—IL PSO (Italian Landscape Psoriasis)
Paolo Gisondi;Francesco Bellinato;
2025-01-01
Abstract
There is still a lack of knowledge on the characteristics of super responders (SRs) during treatment with bimeki- zumab, since genetic, clinical, and biomarkers investiga- tions are required. During bimekizumab treatment, a high rate of SRs was demonstrated at early clinical timepoints, with some interesting diferences between SRs and non-super- respnders.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Esposito_et_al-2025-Clinical_Drug_Investigation.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
957.14 kB
Formato
Adobe PDF
|
957.14 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
